Systematic review assesses treatment effectiveness for Dientamoeba fragilis, indicating potential options for symptomatic infections.
Limited data compiled in this meta-analysis supports the use of paromomycin or clioquinol for treatment of D. fragilis symptomatic infection, in case a decision to treat this pathogen is taken. Future studies correlating clinical efficacy with microbiological eradication are needed.
No takes yet. Share an insight, caveat, or question.
Baharav et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: